Reply to "Innovation and off-label use, the French case and more" by Braillon and Lexchin.
作者信息
Borysowski Jan, Ehni Hans-Jörg, Górski Andrzej
机构信息
Centre for Studies on Research Integrity, Institute of Law Studies, Polish Academy of Sciences, Warsaw, Poland.
Department of Clinical Immunology, Medical University of Warsaw, Warsaw, Poland.
出版信息
Br J Clin Pharmacol. 2019 Oct;85(10):2448-2449. doi: 10.1111/bcp.14068. Epub 2019 Aug 13.
Abstract
摘要
相似文献
1
Reply to "Innovation and off-label use, the French case and more" by Braillon and Lexchin.对布拉永（Braillon）和莱克欣（Lexchin）所著的《创新与超说明书用药：法国案例及其他》的回复
Br J Clin Pharmacol. 2019 Oct;85(10):2448-2449. doi: 10.1111/bcp.14068. Epub 2019 Aug 13.
2
Innovation and off-label use, the French case and more.创新与超说明书用药，以法国为例及其他情况。
Br J Clin Pharmacol. 2019 Oct;85(10):2446-2447. doi: 10.1111/bcp.13993. Epub 2019 Jun 4.
3
Off-label Use of Medications-Reply.药物的非标签使用——回复
JAMA. 2018 Jul 17;320(3):307-308. doi: 10.1001/jama.2018.6521.
4
In Defense of Off-label Prescribing-Reply.关于超说明书用药的辩护——回应
JAMA Intern Med. 2016 Jun 1;176(6):861-2. doi: 10.1001/jamainternmed.2016.1406.
5
Challenges to the validity of using medicine labels to categorize clinical behavior: An empirical and normative critique of "off-label" prescribing.使用药品标签对临床行为进行分类的有效性面临的挑战：对“超说明书”用药的实证与规范批判。
J Eval Clin Pract. 2017 Jun;23(3):574-581. doi: 10.1111/jep.12673. Epub 2016 Nov 14.
6
Addressing innovative off-label medication use at an academic medical center.在学术医疗中心应对创新的非标签药物使用问题。
Am J Health Syst Pharm. 2015 Mar 15;72(6):469-77. doi: 10.2146/ajhp140306.
7
Undermining the hippocratic oath: the Medical Innovation Bill.破坏希波克拉底誓言：《医疗创新法案》
Lancet Oncol. 2015 Jan;16(1):1. doi: 10.1016/S1470-2045(14)71139-8. Epub 2014 Nov 28.
8
Off-label prescribing: in search of a reasonable patient-centered approach.超说明书用药：探寻合理的以患者为中心的方法。
J Pain Palliat Care Pharmacother. 2012 Jun;26(2):131-3. doi: 10.3109/15360288.2012.679335.
9
The challenge of off-label prescribing.
Int J Palliat Nurs. 2015 Sep;21(9):419. doi: 10.12968/ijpn.2015.21.9.419.
10
Off-label baclofen prescribing practices among French alcohol specialists: results of a national online survey.法国酒精问题专家中巴氯芬的超说明书用药情况：一项全国性在线调查结果
PLoS One. 2014 Jun 2;9(6):e98062. doi: 10.1371/journal.pone.0098062. eCollection 2014.
本文引用的文献
1
Innovation and off-label use, the French case and more.创新与超说明书用药，以法国为例及其他情况。
Br J Clin Pharmacol. 2019 Oct;85(10):2446-2447. doi: 10.1111/bcp.13993. Epub 2019 Jun 4.
2
Ethics codes and use of new and innovative drugs.伦理学准则与新型创新药物的使用。
Br J Clin Pharmacol. 2019 Mar;85(3):501-507. doi: 10.1111/bcp.13833. Epub 2019 Jan 4.
3
Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment.美国食品药品监督管理局未给出适应症并不应限制获得适当治疗的机会。
J Am Acad Dermatol. 2019 Feb;80(2):577-578. doi: 10.1016/j.jaad.2018.09.016. Epub 2018 Sep 20.
4
Controversies in off-label prescriptions in dermatology: the perspective of the patient, the physician, and the pharmaceutical companies.皮肤科超适应证处方的争议：患者、医生和制药公司的观点。
Int J Dermatol. 2019 Jul;58(7):788-794. doi: 10.1111/ijd.14222. Epub 2018 Aug 31.
5
Off-label treatments were not consistently better or worse than approved drug treatments in randomized trials.在随机试验中，标签外治疗并不比批准的药物治疗更好或更差。
J Clin Epidemiol. 2018 Feb;94:35-45. doi: 10.1016/j.jclinepi.2017.11.006. Epub 2017 Nov 13.
6
Paediatric Drug Development and Formulation Design-a European Perspective.儿科药物研发与制剂设计——欧洲视角
AAPS PharmSciTech. 2017 Feb;18(2):241-249. doi: 10.1208/s12249-016-0558-3. Epub 2016 Jun 7.
7
Association of Off-label Drug Use and Adverse Drug Events in an Adult Population.成人人群中药物的标签外使用与药物不良事件的关联性。
JAMA Intern Med. 2016 Jan;176(1):55-63. doi: 10.1001/jamainternmed.2015.6058.
8
Off-label use of approved drugs: therapeutic opportunity and challenges.已批准药物的非标签使用：治疗机遇与挑战。
J Am Soc Nephrol. 2004 Mar;15(3):830-1. doi: 10.1097/01.asn.0000118323.41076.01.
Zotero 插件